Vimarsana
Biggest News Aggregation in the World

Mathias Hothum News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mathias Hothum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mathias Hothum Today - Breaking & Trending Today

Heidelberg Pharma : Agenda and convening of the general meeting - Vimarsana News

Heidelberg Pharma : Agenda and convening of the general meeting

Convenience Translation of Heidelberg Pharma AG is the one written in German language.) Heidelberg Pharma AG ... | April 11, 2023

Immatics Announces Full Year 2022 Financial Results and Corporate Update - Vimarsana News

Immatics Announces Full Year 2022 Financial Results and Corporate Update

ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target dose in different solid cancers in an interim clinical update in Phase 1a and Phase

Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol® - Vimarsana News

Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol®

News reports, trends, analysis and Daily Updates on Business, New Emerging Technology, Startups, Funding, and Innovation in India and across the World

Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol® - Vimarsana News

Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol®

/PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free...

Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol - Vimarsana News

Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol

HEIDELBERG, Germany, and CAMBRIDGE, MA, Aug. 9, 2022 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol water-free technology, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for CyclASol (cyclosporine ophthalmic solution), a proposed novel treatment for the signs and symptoms of dry eye disease (DED). CyclASol has demonstrated in two pivotal studies fast onset of therapeutic effect in the indication, clinical meaningful improvemen...